Pfizer to Discontinue Its Hemophilia B Gene Therapy

(MedPage Today) — Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec (Beqvez) across all global markets, citing weak demand.

“Pfizer has made the decision to cease further…

Source link : https://www.medpagetoday.com/hematologyoncology/hemophilia/114319

Author :

Publish date : 2025-02-21 16:27:24

Copyright for syndicated content belongs to the linked Source.